University of Arizona Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Babiker, Hani
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
NCT05223816: An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Recruiting
2
97
US
VG161, Nivolumab Injection [Opdivo]
Virogin Biotech Canada Ltd
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
10/25
12/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
NCT04605913: Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Recruiting
1/2
40
US
Modified GCN+TTF treatment, NovoTTF-100L(P)
Mayo Clinic, NovoCure Ltd.
Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
03/25
03/26
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
SRN-707-001, NCT05037149: Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Active, not recruiting
1
50
US
STP707, STP707 Powder for Injection
Sirnaomics
Solid Tumor
03/24
03/24
NCT05115292: A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

Active, not recruiting
1
85
US
BJ-005
BJ Bioscience, Inc.
Advanced Solid Tumor or Lymphoma
10/24
10/25
NCT04328740: Phase 1 Study of Oral TP-1454

Active, not recruiting
1
31
US
TP-1454 monotherapy
Sumitomo Pharma America, Inc.
Advanced Solid Tumor, Anal Cancer
03/25
05/25
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
Hodges, Megan
NCT05023486: NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
140
US
NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
Novita Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumor Malignancies
09/25
09/25
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
657
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
06/26
11/26
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
MAST, NCT05346484: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Recruiting
1
100
US, RoW
CF33-hNIS, VAXINIA, HOV2, Pembrolizumab, KEYTRUDA®
Imugene Limited
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
12/24
01/25
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
Segar, Jennifer M
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
NCT05023486: NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
140
US
NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
Novita Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumor Malignancies
09/25
09/25
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25

Download Options